RE: AIM Journal10 Dec 2024 12:53
The question in the Proactive interview was likely aimed at confirming whether work on Methods A and B was still ongoing and not stagnating since the August update, particularly as recent updates have focused on Method C. After confirming that progress is still being made on Methods A and B, FG reiterated the information from the 15th August RNS. It’s worth noting that FG has always taken this approach of confirming what has already been officially communicated to ensure no new material information is disseminated.
Is revenue still possible? Yes, it remains a possibility, as the company has not stated otherwise. The new setup was intended to accelerate progress toward this goal. Whether it has succeeded or not remains unclear, and a proper update is needed to confirm. The argument that less time remaining in the year automatically makes revenue highly unlikely is a hasty generalisation—progress can occur rapidly once key milestones are achieved.
Even with just a few weeks left in the year, there’s still a chance for progress or announcements. QBT has shown adaptability, and breakthroughs can sometimes materialise quickly once the groundwork is in place. That said, it’s possible the company is holding back updates for strategic reasons, such as ensuring their real time testing results are robust before disclosing them to the market, as they did when announcing the 2.6x lab improvement for Method B. This approach would align with FG’s careful communication strategy to release only substantiated and meaningful updates.
Sign In
Follow the stocks
